X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse SUVEN LIFE with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SUVEN LIFESCIENCES   ACTAVIS
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-18
ACTAVIS
Dec-18
SUVEN LIFESCIENCES/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs25113,473-   
Low Rs1559,038-   
Sales per share (Unadj.) Rs49.13,305.0-  
Earnings per share (Unadj.) Rs9.7-1,064.5-  
Cash flow per share (Unadj.) Rs11.4348.3-  
Dividends per share (Unadj.) Rs1.500-  
Dividend yield (eoy) %0.70-  
Book value per share (Unadj.) Rs60.313,631.7-  
Shares outstanding (eoy) m127.28332.60-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.13.4 121.3%   
Avg P/E ratio x20.9-10.6 -197.5%  
P/CF ratio (eoy) x17.832.3 55.1%  
Price / Book Value ratio x3.40.8 407.6%  
Dividend payout %15.40-   
Avg Mkt Cap Rs m25,8253,743,642 0.7%   
No. of employees `0001.116.9 6.3%   
Total wages/salary Rs m6130-   
Avg. sales/employee Rs Th5,832.665,044.3 9.0%   
Avg. wages/employee Rs Th571.50-   
Avg. net profit/employee Rs Th1,153.8-20,950.8 -5.5%   
INCOME DATA
Net Sales Rs m6,2531,099,249 0.6%  
Other income Rs m23321,021 1.1%   
Total revenues Rs m6,4851,120,270 0.6%   
Gross profit Rs m1,98228,806 6.9%  
Depreciation Rs m213469,905 0.0%   
Interest Rs m4663,433 0.1%   
Profit before tax Rs m1,955-483,511 -0.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0123,315 0.0%   
Tax Rs m718-6,127 -11.7%   
Profit after tax Rs m1,237-354,069 -0.3%  
Gross profit margin %31.72.6 1,209.5%  
Effective tax rate %36.71.3 2,898.9%   
Net profit margin %19.8-32.2 -61.4%  
BALANCE SHEET DATA
Current assets Rs m5,622450,854 1.2%   
Current liabilities Rs m1,168398,841 0.3%   
Net working cap to sales %71.24.7 1,505.7%  
Current ratio x4.81.1 426.0%  
Inventory Days Days8120 415.8%  
Debtors Days Days3666 54.2%  
Net fixed assets Rs m3,325124,429 2.7%   
Share capital Rs m1270-   
"Free" reserves Rs m7,5470-   
Net worth Rs m7,6744,533,888 0.2%   
Long term debt Rs m141,596,546 0.0%   
Total assets Rs m9,1357,087,498 0.1%  
Interest coverage x43.2-6.6 -652.7%   
Debt to equity ratio x00.4 0.5%  
Sales to assets ratio x0.70.2 441.3%   
Return on assets %14.0-4.1 -342.5%  
Return on equity %16.1-7.8 -206.4%  
Return on capital %26.0-4.8 -537.8%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m3,0650-   
CASH FLOW
From Operations Rs m699392,720 0.2%  
From Investments Rs m-6215,749 -0.0%  
From Financial Activity Rs m-577-674,025 0.1%  
Net Cashflow Rs m116-65,229 -0.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 69.63 Rs / USD

Compare SUVEN LIFESCIENCES With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare SUVEN LIFESCIENCES With: STRIDES PHARMA SCIENCE  ABBOTT INDIA  FDC LTD.  NOVARTIS  SUN PHARMA  



Today's Market

Sensex Ends 71 Points Lower; Metal and Energy Stocks Witness Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their volatile trading day marginally lower.

Related Views On News

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFE Announces Quarterly Results (3QFY19); Net Profit Down 27.1% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUVEN LIFE has posted a net profit of Rs 252 m (down 27.1% YoY). Sales on the other hand came in at Rs 1 bn (down 21.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

SUVEN LIFE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

Here's an analysis of the annual report of SUVEN LIFE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFE. Also includes updates on the valuation of SUVEN LIFE.

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

7 Bluechips to Profit from Tech Disruption(Profit Hunter)

Jun 17, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Jun 24, 2019 (Close)

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES 5-YR ANALYSIS

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS